This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIAK0G1_L.jpg
Merck’s offer of $36 per share in cash for Imago represents nearly a 107% premium to the company’s last closing price.
The deal for the clinical-stage biopharmaceutical company that is developing drugs for the treatment of bone marrow-related diseases is expected to close in the first quarter of 2023, Merck said.
